Psoriasis drug may also aid weight loss
Nearly 20% of patients lost more than 5% of their baseline weight by 52 weeks or less when assigned to receive apremilast.
Nearly 20% of patients lost more than 5% of their baseline weight by 52 weeks or less when assigned to receive apremilast.
Patients with psoriasis should avoid long-term use of medications that are toxic to the kidneys.
Patient with psoriasis were unsuccessfully treated with conventional therapies before treatment with biologics.
Patients with psoriasis do not have an increased of major cardiovascular events like heart attack and stroke.
Patients taking adalimumab saw quicker treatment of their psoriasis than those taking methotrexate.
Male patients with psoriasis have higher levels of estradiol and lower levels of testosterone compared with controls.
The rate of reported adverse events was comparable in both the treatment and placebo groups.
These study findings confirm that the therapeutic silencing of IL-23 is a potential target for psoriasis prevention and management.
The presence of snoring was not associated with a higher risk of psoriasis.
This discovery could prevent progression of psoriatic arthritis in patients with psoriasis.